Benchling brings chemistry and biology together on one R&D platform, adds chemistry reactions and predictive models. * By Benchling * Aug 20, 2026 Updated Aug 20, 2026 * 0 SAN FRANCISCO, Aug. 20, 2026 /PRNewswire/ - Benchling today announced its expansion into chemistry, bringing chemistry and biology together on one connected platform for scientific research and development. As part of this expansion, Benchling is launching Reactions, a new capability for planning and modeling single-step synthesis, and adding predictive models for small molecule R&D from Inductive Bio. For more than a decade, Benchling has been the market leader at large molecule R&D. As research has evolved, therapeutic modalities are increasingly crossing the boundary between biology and chemistry. In addition, advances in AI create new opportunities to learn from data across the entire R&D organization. This makes a connected, structured data foundation more important than ever. That's why Benchling is bringing molecules and reactions together with experiments, biological results, and computational predictions, so teams work across modalities in one system, and put their scientific data to work with AI. Expanding Benchling for chemistry Chemistry moves in a tight, iterative loop: decide what to make, determine how to make it, synthesize and characterize it, test it, learn, and repeat. But the data behind that loop often lives across disconnected tools, making it hard to understand how a molecule was made and performed, and what to do next. Reactions is an important step in a broader effort to bring more of the chemistry workflow into Benchling, beginning with the foundational workflows chemists use every day. Reactions is built on the same structured platform as the rest of Benchling. Chemists can search across reactions and notebook entries, while every molecule stays linked into the customer's broader scientific record, connecting synthesis with the experiments, results, and other scientific context around it. A chemist designing a new analog can search related molecules and past reactions, plan synthesis with automatically calculated stoichiometry, account for salts and solvates, and capture the resulting product in the same scientific record. When that molecule moves into testing, its history stays connected. Teams trace how it was made, see its experimental and biological results, compare it with related chemistry, and carry those insights into the next design decision. With Reactions, teams can: * Plan synthesis with less manual work. Sketch single-step reactions directly or bring them in from existing reaction files, like ChemDraw, then automatically calculate stoichiometry and quantities as reaction conditions change. * Work with chemically meaningful forms. Use shared salt and solvate libraries and account for salt forms during reaction planning. * Learn from chemistry the team has already done. Find past reactions by chemical structure or similarity, then narrow results by reactants, products, solvents, catalysts, and reaction role. * Work with molecules alongside their synthesis history. Capture and find molecular structures in Benchling alongside the reactions in which they were made or used. * Keep the molecule's story connected. Automatically link reactions to compounds, experiments, and biological results so synthesis history and downstream performance can be explored together. Bringing predictions into the design cycle Benchling Model Hub brings computational predictions into that decision-making loop, alongside the experimental data scientists already use. As we expand our support for small molecule R&D, we're also bringing more chemistry-focused scientific models into Model Hub. Inductive Bio's ADMET prediction models enable any chemist using Benchling to predict the chemical and pharmacokinetic properties that determine whether a molecule can become a viable drug. Inductive Bio's models are independently validated by three consecutive first place performances in the OpenADMET blind prediction challenges. Scientists can register proposed molecules in Benchling, run predictions before physical ADMET testing, and compare those predictions with experimental results from compounds they've already made. That combined evidence helps teams make better decisions about what to synthesize next and move through design cycles faster. We're just getting started Chemistry is currently in limited availability. Request access here: benchling.com/chemistry-la-signup. About Benchling Benchling is the AI platform for biotech R&D, unifying scientific data and automating workflows to accelerate discovery and development. Trusted by more than 1,300 companies worldwide, from pioneering startups to global leaders like Merck, Moderna, and Sanofi, Benchling gives scientists a single place to capture, connect, and act on data across the entire R&D lifecycle. With Benchling AI, agents and models work directly inside scientific workflows, grounded in structured data. The result is faster teams, better molecules, and breakthroughs that reach the world sooner. SOURCE Benchling Submit your news. We're always interested in hearing about news in our community. Let us know what's going on!

Cognizant and Benchling selected as partners to accelerate Kyowa Kirin's R&D. Aug 16, 2026, 22:00 ET Transforming the Research Lifecycle Through Integrated Data Management, Advanced Automation, and AI-Driven Workflows TOKYO, Aug. 16, 2026 /PRNewswire/ - Cognizant (NASDAQ: CTSH) today announced that it will support the introduction and implementation of Benchling, the AI platform for R&D at Tokyo Research Park and Fuji Research Park, research sites in Japan operated by Kyowa Kirin Co., Ltd. Benchling gives scientists a single place to capture structured data, run AI models and agents and automate the workflows that move discovery and development forward. Through Cognizant's implementation support, researchers in the Research Division of Kyowa Kirin will be able to efficiently and seamlessly conduct a range of research activities, from experiment planning and execution to data collection and use of AI, within a single environment. This implementation demonstrates Kyowa Kirin's strong commitment to accelerating R&D productivity by addressing an expanding pipeline and increasingly advanced and diverse research needs. Cognizant will support this effort through centralized data management, enhanced molecular design processes and workflow automation. Kyowa Kirin is a global specialty pharmaceutical company with strengths in specific disease areas, including bone and mineral disorders, intractable hematologic diseases and hemato oncology and rare diseases. At its three research facilities worldwide, the company is pursuing innovative modalities such as advanced antibody technologies and hematopoietic stem cell gene therapy. By integrating "disease science" with "drug discovery technologies" that identify optimal solutions based on scientific insights, Kyowa Kirin is accelerating the creation of life-changing value. To further advance these initiatives, the company needed a platform that could support cutting-edge scientific research through automation and AI, together with an experienced implementation partner to deploy, operate and manage it at scale. With this implementation, Benchling is expected to help automate experimental design and data collection, accelerating the research cycle from drug discovery target identification through to new drug candidate selection. Benchling connects directly with Kyowa Kirin's laboratory instruments, enabling data to be captured automatically as structured, searchable records without manual entry. Benchling also supports collaboration across the research process and provides Kyowa Kirin's researchers with agentic and analytical capabilities that understand scientific context. In addition, the AI platform is expected to help researchers conduct molecular design, access years of experimental history, generate reports and analyze relationships across research activities more efficiently. In collaboration with Benchling, Cognizant is expected to provide end-to-end support across the entire process, from platform setup to data migration, system implementation and ongoing maintenance following deployment. In addition, by optimizing data flows in line with the expansion of research scale, Cognizant is expected to help improve researcher productivity and support more informed decision-making. By providing products and services under a single contract, Kyowa Kirin aims to enhance cost predictability while reducing large capital expenditures and enabling flexible cost management as operating expenses. "Through the implementation of Benchling under the partnership with Cognizant, we expect to promote the standardization of workflows and the structuring of data in research environments," said Takashi Shimada, Head of Research Division, Kyowa Kirin Co., Ltd. "By enhancing the entire research process, we aim to establish a next-generation drug discovery foundation capable of continuously creating innovative new medicines." "Kyowa Kirin is transforming its research processes to address some of the most difficult challenges in healthcare and to deliver innovative new medicines to patients as quickly as possible," said Sajith Wickramasekara, co-founder and CEO, Benchling. "Benchling embeds AI into daily workflows, connected to years of accumulated experimental data and context. In biopharma research and development, the speed and quality of research cycles have a direct impact on patients. AI only becomes meaningful when it proves its value in these real-world settings." "Our partnership with Kyowa Kirin in implementing Benchling will help redefine the company's pursuit of scientific excellence, drug discovery research and laboratory operations and establish a new benchmark for business engagement," said Archana Ramanakumar, Industry Solutions Leader and Senior Vice President, Cognizant. "We are confident that this innovative and future-oriented collaboration will create a solid success story." "Kyowa Kirin is revolutionizing its research processes through the implementation of Benchling and collaboration with Cognizant," said Nobuhiko Watanabe, President and Representative Director, Cognizant Japan. "This initiative is expected to significantly improve drug discovery efficiency and further strengthen the company's position in the Japanese market." About Cognizant Cognizant (NASDAQ: CTSH), as an AI builder and technology services provider, bridges the gap between AI investment and enterprise value by building full-stack AI solutions for clients. Leveraging our deep expertise in industries, business processes, and engineering, we embed each organization's unique business environment into technology systems. In doing so, we help unlock human potential, deliver tangible results, and enable global enterprises to stay ahead in a rapidly changing world. For more information, please visit www.cognizant.ai or @cognizant. About Benchling Benchling is the leading AI platform for biotech R&D, unifying scientific data and automating workflows to accelerate discovery and development. Trusted by more than 1,300 companies worldwide, from pioneering startups to global leaders like Merck, Moderna and Sanofi, Benchling gives scientists a single place to capture, connect and act on data across the entire R&D lifecycle. With Benchling AI, agents and models work directly inside scientific workflows, grounded in structured data. The result is faster teams, better molecules and breakthroughs that reach the world sooner. https://www.benchling.com/ About Kyowa Kirin Kyowa Kirin is deeply committed to creating and delivering new medicines and treatments with life-changing value to patients. As a Japan-based global specialty pharmaceutical company, Kyowa Kirin has contributed to the creation of medicines and innovation in biotechnology for more than 70 years. Today, the company is working to develop next-generation antibody drugs and gene and cell therapies that have the potential to address significant unmet medical needs. In particular, Kyowa Kirin focuses on research and development of treatments for bone and mineral disorders, hemato oncology and intractable hematologic diseases and rare diseases, while seeking to maximize the value of research outcomes that may be applied in other therapeutic areas through partnerships. Guided by shared values, Kyowa Kirin is committed to achieving sustainable growth and bringing smiles to people's lives. https://www.kyowakirin.com/index.html Media contacts

Cognizant and Benchling selected as partners to accelerate Kyowa Kirin's R&D. * By Cognizant Technology Solutions * 15 hrs ago Transforming the Research Lifecycle Through Integrated Data Management, Advanced Automation, and AI-Driven Workflows TOKYO, Aug. 16, 2026 /PRNewswire/ - Cognizant (NASDAQ: CTSH) today announced that it will support the introduction and implementation of Benchling, the AI platform for R&D at Tokyo Research Park and Fuji Research Park, research sites in Japan operated by Kyowa Kirin Co., Ltd. Benchling gives scientists a single place to capture structured data, run AI models and agents and automate the workflows that move discovery and development forward. Through Cognizant's implementation support, researchers in the Research Division of Kyowa Kirin will be able to efficiently and seamlessly conduct a range of research activities, from experiment planning and execution to data collection and use of AI, within a single environment. This implementation demonstrates Kyowa Kirin's strong commitment to accelerating R&D productivity by addressing an expanding pipeline and increasingly advanced and diverse research needs. Cognizant will support this effort through centralized data management, enhanced molecular design processes and workflow automation. Kyowa Kirin is a global specialty pharmaceutical company with strengths in specific disease areas, including bone and mineral disorders, intractable hematologic diseases and hemato oncology and rare diseases. At its three research facilities worldwide, the company is pursuing innovative modalities such as advanced antibody technologies and hematopoietic stem cell gene therapy. By integrating "disease science" with "drug discovery technologies" that identify optimal solutions based on scientific insights, Kyowa Kirin is accelerating the creation of life-changing value. To further advance these initiatives, the company needed a platform that could support cutting-edge scientific research through automation and AI, together with an experienced implementation partner to deploy, operate and manage it at scale. With this implementation, Benchling is expected to help automate experimental design and data collection, accelerating the research cycle from drug discovery target identification through to new drug candidate selection. Benchling connects directly with Kyowa Kirin's laboratory instruments, enabling data to be captured automatically as structured, searchable records without manual entry. Benchling also supports collaboration across the research process and provides Kyowa Kirin's researchers with agentic and analytical capabilities that understand scientific context. In addition, the AI platform is expected to help researchers conduct molecular design, access years of experimental history, generate reports and analyze relationships across research activities more efficiently. In collaboration with Benchling, Cognizant is expected to provide end-to-end support across the entire process, from platform setup to data migration, system implementation and ongoing maintenance following deployment. In addition, by optimizing data flows in line with the expansion of research scale, Cognizant is expected to help improve researcher productivity and support more informed decision-making. By providing products and services under a single contract, Kyowa Kirin aims to enhance cost predictability while reducing large capital expenditures and enabling flexible cost management as operating expenses. "Through the implementation of Benchling under the partnership with Cognizant, we expect to promote the standardization of workflows and the structuring of data in research environments," said Takashi Shimada, Head of Research Division, Kyowa Kirin Co., Ltd. "By enhancing the entire research process, we aim to establish a next-generation drug discovery foundation capable of continuously creating innovative new medicines." "Kyowa Kirin is transforming its research processes to address some of the most difficult challenges in healthcare and to deliver innovative new medicines to patients as quickly as possible," said Sajith Wickramasekara, co-founder and CEO, Benchling. "Benchling embeds AI into daily workflows, connected to years of accumulated experimental data and context. In biopharma research and development, the speed and quality of research cycles have a direct impact on patients. AI only becomes meaningful when it proves its value in these real-world settings." "Our partnership with Kyowa Kirin in implementing Benchling will help redefine the company's pursuit of scientific excellence, drug discovery research and laboratory operations and establish a new benchmark for business engagement," said Archana Ramanakumar, Industry Solutions Leader and Senior Vice President, Cognizant. "We are confident that this innovative and future-oriented collaboration will create a solid success story." "Kyowa Kirin is revolutionizing its research processes through the implementation of Benchling and collaboration with Cognizant," said Nobuhiko Watanabe, President and Representative Director, Cognizant Japan. "This initiative is expected to significantly improve drug discovery efficiency and further strengthen the company's position in the Japanese market." About Cognizant Cognizant (NASDAQ: CTSH), as an AI builder and technology services provider, bridges the gap between AI investment and enterprise value by building full-stack AI solutions for clients. Leveraging its deep expertise in industries, business processes, and engineering, The Daily Times embed each organization's unique business environment into technology systems. In doing so, The Daily Times help unlock human potential, deliver tangible results, and enable global enterprises to stay ahead in a rapidly changing world. For more information, please visit www.cognizant.ai or @cognizant. About Benchling Benchling is the leading AI platform for biotech R&D, unifying scientific data and automating workflows to accelerate discovery and development. Trusted by more than 1,300 companies worldwide, from pioneering startups to global leaders like Merck, Moderna and Sanofi, Benchling gives scientists a single place to capture, connect and act on data across the entire R&D lifecycle. With Benchling AI, agents and models work directly inside scientific workflows, grounded in structured data. The result is faster teams, better molecules and breakthroughs that reach the world sooner. https://www.benchling.com/ About Kyowa Kirin Kyowa Kirin is deeply committed to creating and delivering new medicines and treatments with life-changing value to patients. As a Japan-based global specialty pharmaceutical company, Kyowa Kirin has contributed to the creation of medicines and innovation in biotechnology for more than 70 years. Today, the company is working to develop next-generation antibody drugs and gene and cell therapies that have the potential to address significant unmet medical needs. In particular, Kyowa Kirin focuses on research and development of treatments for bone and mineral disorders, hemato oncology and intractable hematologic diseases and rare diseases, while seeking to maximize the value of research outcomes that may be applied in other therapeutic areas through partnerships. Guided by shared values, Kyowa Kirin is committed to achieving sustainable growth and bringing smiles to people's lives. Media contacts Name: Alex Dudley Europe / APAC Name: Sarah Douglas Name: Vipin Nair SOURCE Cognizant Technology Solutions